185 related articles for article (PubMed ID: 37180147)
1. Guillain-Barré syndrome and COVID-19 vaccines: focus on adenoviral vectors.
Rzymski P
Front Immunol; 2023; 14():1183258. PubMed ID: 37180147
[TBL] [Abstract][Full Text] [Related]
2. Guillain-Barré syndrome after COVID-19 vaccination: A systematic review and analysis of case reports.
Abuawwad MT; Taha MJJ; Taha AJ; Kozaa YA; Falah O; Abuawwad IT; Hammad EM; Mahmoud AA; Aladawi M; Serhan HA
Clin Neurol Neurosurg; 2024 Mar; 238():108183. PubMed ID: 38401232
[TBL] [Abstract][Full Text] [Related]
3. Guillain-Barré Syndrome Following the BNT162b2 mRNA COVID-19 Vaccine.
Algahtani HA; Shirah BH; Albeladi YK; Albeladi RK
Acta Neurol Taiwan; 2023 Jun; 32(2)():82-85. PubMed ID: 37198513
[TBL] [Abstract][Full Text] [Related]
4. Guillain-Barré syndrome in an era of global infections and 21st century vaccination.
Lunn MP
Curr Opin Neurol; 2022 Oct; 35(5):571-578. PubMed ID: 36069416
[TBL] [Abstract][Full Text] [Related]
5. Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study.
Ha J; Park S; Kang H; Kyung T; Kim N; Kim DK; Kim H; Bae K; Song MC; Lee KJ; Lee E; Hwang BS; Youn J; Seok JM; Park K
Sci Rep; 2023 Mar; 13(1):3773. PubMed ID: 36882454
[TBL] [Abstract][Full Text] [Related]
6. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
[TBL] [Abstract][Full Text] [Related]
7. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.
García-Grimshaw M; Michel-Chávez A; Vera-Zertuche JM; Galnares-Olalde JA; Hernández-Vanegas LE; Figueroa-Cucurachi M; Paredes-Ceballos O; Reyes-Terán G; Carbajal-Sandoval G; Ceballos-Liceaga SE; Arauz A; Valdés-Ferrer SI
Clin Immunol; 2021 Sep; 230():108818. PubMed ID: 34358692
[TBL] [Abstract][Full Text] [Related]
8. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
Introna A; Caputo F; Santoro C; Guerra T; Ucci M; Mezzapesa DM; Trojano M
Clin Neurol Neurosurg; 2021 Sep; 208():106887. PubMed ID: 34418708
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.
García-Grimshaw M; Galnares-Olalde JA; Bello-Chavolla OY; Michel-Chávez A; Cadena-Fernández A; Briseño-Godínez ME; Antonio-Villa NE; Núñez I; Gutiérrez-Romero A; Hernández-Vanegas L; Del Mar Saniger-Alba M; Carrillo-Mezo R; Ceballos-Liceaga SE; Carbajal-Sandoval G; Flores-Silva FD; Díaz-Ortega JL; Cortes-Alcalá R; Pérez-Padilla JR; López-Gatell H; Chiquete E; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
Eur J Neurol; 2022 Nov; 29(11):3368-3379. PubMed ID: 35841212
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
[TBL] [Abstract][Full Text] [Related]
11. Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.
Leung C
Hum Vaccin Immunother; 2021 Sep; 17(9):2957-2958. PubMed ID: 34032555
[TBL] [Abstract][Full Text] [Related]
12. Sensory Ataxic Guillain-Barré Syndrome with Dysgeusia after mRNA COVID-19 Vaccination.
Ogata S; Ishii Y; Asano K; Kobayashi E; Kubota S; Takahashi K; Miyaji Y; Higashiyama Y; Joki H; Doi H; Koga M; Takeuchi H; Tanaka F
Intern Med; 2022 Jun; 61(11):1757-1760. PubMed ID: 35342134
[TBL] [Abstract][Full Text] [Related]
13. Association Between Guillain-Barré Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
Bishara H; Arbel A; Barnett-Griness O; Bloch S; Cohen S; Najjar-Debbiny R; Gronich N; Auriel E; Saliba W
Neurology; 2023 Nov; 101(20):e2035-e2042. PubMed ID: 37852786
[TBL] [Abstract][Full Text] [Related]
14. Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.
Kim JE; Park J; Min YG; Hong YH; Song TJ
J Peripher Nerv Syst; 2022 Sep; 27(3):206-214. PubMed ID: 35751472
[TBL] [Abstract][Full Text] [Related]
15. Guillain-Barré Syndrome After Ad26.COV2.S Vaccination.
Thant HL; Morgan R; Paese MM; Persaud T; Diaz J; Hurtado L
Am J Case Rep; 2022 Feb; 23():e935275. PubMed ID: 35157644
[TBL] [Abstract][Full Text] [Related]
16. Guillain-Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis.
Censi S; Bisaccia G; Gallina S; Tomassini V; Uncini A
J Neurol; 2024 Mar; 271(3):1063-1071. PubMed ID: 38233678
[TBL] [Abstract][Full Text] [Related]
17. Effects of COVID-19 vaccine type on Guillain-Barré syndrome: Two cases and a literature review.
Lee HY; Lien WC
Hum Vaccin Immunother; 2023 Dec; 19(1):2171231. PubMed ID: 36919452
[TBL] [Abstract][Full Text] [Related]
18. A Case Report of Guillain-Barré Syndrome In Association with SARS-CoV-2 Vaccination in Malaysia.
Sii HL; Ng SH; Wong VF; Law WC
Acta Neurol Taiwan; 2023 Dec; 32(4)():207-211. PubMed ID: 37723913
[TBL] [Abstract][Full Text] [Related]
19. Rare cases of Guillain-Barré syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021.
Lehmann HC; Oberle D; Keller-Stanislawski B; Rieck T; Streit R
Euro Surveill; 2023 Jun; 28(24):. PubMed ID: 37318764
[TBL] [Abstract][Full Text] [Related]
20. Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
Folegatti PM; Jenkin D; Morris S; Gilbert S; Kim D; Robertson JS; Smith ER; Martin E; Gurwith M; Chen RT;
Vaccine; 2022 Aug; 40(35):5248-5262. PubMed ID: 35715352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
